1. IAPP/amylin and β-cell failure: implication of the risk factors of type 2 diabetes

   • Azuma Kanatsuka
   • Shigetake Kou
   • Hideichi Makino

   Review Article 21 February 2018 Pages: 143 - 157

   

2. Factors involved in decreasing the therapeutic effect of sitagliptin: a subanalysis of the JAMP study

   • Hideo Nunome
   • Hiroshi Sakura
   • for the JAMP Study Investigators

   Original Article 16 December 2017 Pages: 158 - 167

   

3. Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study

   • Takahisa Hirose
   • Chihiro Saitoh
   • Nobuo Kondo

   Original Article 12 January 2018 Pages: 168 - 178

   

4. Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease

   • Akihiko Nakamura
   • Ryo Kodera
   • Hirofumi Makino

   Original Article 18 January 2018 Pages: 179 - 188

   

5. Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study

   • Tomoyuki Iwasaki
   • Takaomi Kessoku
   • Masato Yoneda

   Original Article 02 February 2018 Pages: 189 - 195

   

6. A case of hyperinsulinemic hypoglycemia related with a calcimimetic agent

   • Satoru Takashima
   • Takuma Narita
   • Yuichiro Yamada

   Case Report 21 February 2018 Pages: 196 - 200

   

7. Effect of switching from conventional continuous subcutaneous insulin infusion to sensor augmented pump therapy on glycemic profile in Japanese patients with type 1 diabetes

   • Atsuko Matsuoka
   • Yushi Hirota
   • Wataru Ogawa

   Short Communication 22 January 2018 Pages: 201 - 207